argenx

argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. It evaluates efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

April 28, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 5, 2022 at 2:30 pm CET (8:30 am ET) to discuss its first quarter 2022 financial results and provide a business update.

argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 2022

Interim data suggest long-term treatment with VYVGART provides improvement in generalized myasthenia gravis (gMG) disease scores that remains consistent over multiple treatment cycles

argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART® (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting

BREDA, the Netherlands--(BUSINESS WIRE)--argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting

argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting

argenx announces Annual General Meeting of Shareholders on May 10, 2022

Regulated information — Inside information

argenx raises $700 million in gross proceeds in a global offering

argenx (ARGX) plans to file a BLA for the SC formulation of efgartigimod, developed using Halozyme's ENHANZE technology, for treating myasthenia gravis disease, an autoimmune disorder, in 2022.

argenx (ARGX) Up on Positive Autoimmune Disorder Study Data

Arcturus Therapeutics

Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical company" to run a clinical trial for LUNAR-COV19 vaccine candidate as a booster.  According to analyst Yasmeen.

Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx

Argenx SE (NASDAQ: ARGX) ) has announced topline data from the Phase 3 ADAPT-SC study evaluating subcutaneous (SC) efgartigimod for generalized myasthenia gravis (gMG).  Myasthenia gravis is a chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles.

Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder

BREDA, the Netherlands--(BUSINESS WIRE)--argenx Announces Positive Topline Phase 3 Data from ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis

argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis

Derivatives markets, used by the market-making community to hedge equity market liquidity trade orders, tell by their component structure and prices the subject stock's expected coming price range limits.

argenx SE: Dutch Biotech Has Near Gain Ahead Says Hedging By Market-Makers

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q4 2021 Results - Earnings Call Transcript

argenx Reports Full Year 2021 Financial Results and Provides Fourth Quarter Business Update

argenx SE (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy argenx SE (ARGX) Ahead of Earnings?

February 28, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the 42nd Annual Cowen Health Care Conference on Monday, March 7, 2022 at 2:10 p.m. E.T.

argenx to Present at the 42nd Annual Cowen Health Care Conference

February 24, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, March 3, 2022 at 2:30 pm CET (8:30 am ET) to discuss its full year 2021 financial results and provide a fourth quarter business update.

argenx to Report Full Year 2021 Financial Results and Fourth Quarter Business Update on March 3, 2022

February 10, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 10:40 a.m. ET.

argenx to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Adagio Therapeutics

Allakos Inc

Alnylam Pharmaceuticals

BridgeBio Pharma Inc

Bicycle Therapeutics Plc - ADR

BioMarin Pharmaceutical

Denali Therapeutics

Incyte

Intra-Cellular Therapies

Jasper Therapeutics

Mirati Therapeutics

Praxis Precision Medicines

SAGE Therapeutics

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double

12 biotech stocks to consider buying now as prospects for the sector brighten this year

BREDA, Netherlands--(BUSINESS WIRE)--argenx Announces VYVGART™ Approval in Japan for the Treatment of Generalized Myasthenia Gravis

argenx Announces VYVGART™ Approval in Japan for the Treatment of Generalized Myasthenia Gravis

BREDA, Netherlands--(BUSINESS WIRE)--argenx Highlights Strategic Priorities for 2022

argenx Highlights Strategic Priorities for 2022

January 3 , 202 2 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 7:30 a.m. ET.

argenx to Present at 40th Annual J.P. Morgan Healthcare Conference

argenx received FDA approval for Vyvgart (efgartigimod) for the treatment of generalized myasthenia gravis. The label looks very favorable, and the only negative is that patients who do not have AChR antibodies are not included.

argenx: Vyvgart's Approval A Key Step For Continued Value Creation

The recent approval of this drugmaker's first product is giving reasons to cheer now, but what about down the road?

Is Argenx a Good Biotech Stock to Buy for 2022?

The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart (efgartigimod alfa-fcab) for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. MG affects multiple muscle groups throughout the body.

Argenx's Vyvgart Wins FDA Approval For Autoimmune, Neuromuscular Disease

BREDA, Netherlands--(BUSINESS WIRE)--Regulatory News: argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved VYVGART™ (efgartigimod alfa-fcab) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. These patients represent appro

argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

Biotech stocks are risky investments and to make a profit informed decision-making is needed. BofA Securities announced its top mid-cap biopharma picks in a note released Tuesday.

News for argenx Stock (ARGX)